XNAS
RPRX
Market cap25bUSD
Oct 08, Last price
56.21USD
1D
-0.97%
1Q
-0.39%
IPO
15.63%
Name
Royalty Pharma PLC
Chart & performance
P/E
32.32
P/S
10.48
EPS
1.74
Div yield, %
1.55%
Shrs. gr., 5y
7.59%
Rev. gr., 5y
2.30%
Revenues
2.38b
+5.06%
Net income
771m
-10.25%
CFO
2.49b
-10.08%
Dividend
Aug 14, 20260.235 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Related entities
Subsidiaries
ROYALTY PHARMA HOLDINGS LTD
Key people
Christopher D. Hite
Vice Chairman of the Board, Executive Vice President · since 2020
Headquarters & legal address
The Pavilions
Bridgwater Road
Bristol BS13 8AE
GB
Bridgwater Road
Bristol BS13 8AE
GB
Previous name
ROYALTY PHARMA LTD
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||